PubMed Health⌕ Search

Biomedical subjects

M Bindi

Publications and source records attributed to M Bindi.

29 records · Page 2Linked to original sources
PubMed1985

Radio-chemotherapeutic management of bone diffusion from breast carcinoma.

A combined modality therapy (irradiation plus low-dose Adriamycin and Cyclophosphamide) was delivered to 41 patient affected by extensive bone diffusion from breast carcinoma. A 36% (15/41) objective response rate was obtained, no change was also detectable in 36%, while progressive disease in 28% (11/41). A subjective response was achieved in 37/41 patients, i.e. 90%. The Authors remark the difficulties in evaluating the objective response of metastatic bone to therapy and confirm the keystone role of radiation therapy in the palliative treatment of breast cancer skeletal diffusion.

Adult↗
PubMed1984

Differential diagnosis between poorly differentiated epidermoid and small cell carcinoma by means of scanning electron microscopy and cytokeratin assay.

18 cases of small cell carcinoma were studied by means of scanning electron microscopy and immunohistochemical analysis. 4 cases showed ultrastructural and immunohistochemical features of poorly differentiated epidermoid carcinoma. A strict correlation has been demonstrated between ultrastructural and immunohistochemical findings.

Aged↗
PubMedDate not supplied

A role for tumor markers in therapeutic decisions after chemotherapy induction of objective remission in stage III epithelial ovarian neoplasms.

The management of advanced stage ovarian carcinomas is presently based on initial surgical debulking, multiple drug chemotherapy including cisplatinum, second-look laparotomy. Such an aggressive approach has improved objective response rates and expected survival time, but no dramatic change has been demonstrated as for definitive cure percentages. Many Authors have attempted to turn an optimal objective response to chemotherapy (no residual or minimal residual disease at second-look) into a definitive cure with irradiation. Some reports show satisfactory results, but a high incidence of bowel obstructive complications has been demonstrated, probably due to multiple surgical manipulations before radiotherapy. A reliable diagnostic tool, that could help to avoid the second-look laparotomy (whose inherent role in improving survival is not assessed) should be therefore useful. The possible role of serum tumor markers determinations, for this purpose, is here discussed on the ground of a series of 20 patients affected by stage III ovarian carcinoma. Following this experience, a valuable role seems attributable to CA 125 in monitoring tumor response. Patients achieving values under 35 U/ml before second-look laparotomy showed tumor residuals in the range O-microscopic- less than 1 cm., that is, neoplastic localizations reliable for consolidation radiation therapy.

Adenocarcinoma↗
PubMedDate not supplied

[Changes in performance status in patients with pulmonary carcinoma treated with mono-fractionation radiotherapy once a week].

45 patients with lung cancer at the III and IV stage were treated with once-a-week radiation therapy. Treatments were carried out with a daily fraction, at beginning, of 880 rad (2100 ret) (14 pz.) and 550 rad (1500 ret) afterwards. In both cases the total dose was 4400 rad. All the patients had symptoms of locally advanced cancer: cough (46%), hemoptysis (31%), dyspnea (62%) and chest pain (28%). All of them were out-patients (ECOG 0-1) and presented a Performance Status by Karnofsky of 50-80. The average age was 60 (median 65, range 38-85) with a raised percent (50%) of collateral illness. The selection of once-a-week technique was determined by the bad prognosis and the necessity of symptoms' control, allowing the patients to stay in his proper social and family group. All the time of therapy and the follow-up the values of Performance Status were assigned scrupulously. The analysis showed that the 80% of the patients had a subjective improvement which lasted, on average, 4 months (range 1-21) with an increase of 20 points of Performance Status after the end of therapies. Concluding, the high percentage of success on symptoms presented by the patients, confirms the validity of weekly radiotherapy, which guarantees, besides the palliative effect, the psychological integrity which is necessary in the last period of the life of cancer patient.

Adult↗
PubMedDate not supplied

[Combined chemo-radiotherapy in non-operable cervico-facial neoplasms. Final results of an experience with non-selected patients].

The management of advanced inoperable head and neck cancer is often based on a combined chemo-radiotherapy approach. No definitive conclusions on the effectiveness of this combination can be drawn from clinical trials because these neoplasms are heterogeneous and treatment schedules vary. Many scientific trials test highly toxic combinations, whereas not only good results but also low toxicity are mandatory in the current practice. We report the results obtained in 90 consecutive patients affected with inoperable head and neck cancers in stages III-IV, or relapsed after surgery. Chemotherapy consisted of a cis-platinum/bleomycin induction phase, followed by weekly administrations of cis-platinum simultaneous with conventional irradiation. The objective remission rates, achieved at the end of the induction chemotherapy and the simultaneous chemo-radiotherapy phases, were respectively 55.5% and 84.5%. The tumor disappeared in 39% of cases, by the end of the whole treatment. With the Kaplan-Meier method, 3-year overall, progression-free and relapse-free survival rates were 21.20%, 22.25% and 38.75%, respectively. The overall survival rate, calculated with the "log-rank" test according to the stage and the site of the primary tumor, exhibited no significant differences. In contrast, significant differences (p < 0.05) were demonstrated, according to treatment intent (curative radical: 26%, vs palliative: 0%) and to the achievement of an objective response at the end of induction chemotherapy--i.e., 48% 3-year survival rate, vs 7% in chemotherapy resistant cancer patients. When limiting the analysis to 72 radically irradiated patients, however, the achievement of CR after induction chemotherapy lost its prognostic value. Toxicity was not substantially higher than with conventional irradiation. Our results are in agreement with literature data on this subject which, regarding survival, fail to prove such integrated treatments as ours better than irradiation alone. In contrast, the preliminary combination of chemotherapy and irradiation is clearly better for the patients waiting to receive radiation therapy, because tumor volume and related symptoms markedly decrease after induction chemotherapy. Currently the best survival rates (about 50% at 3 years) with chemo-radiotherapy are obtained, in this kind of cancer, by combining cis-platinum and continuous-infusion 5-fluorouracil, simultaneous with irradiation. However, frequent and severe toxicity is reported. Should such a modality be adopted in the current practice, patients should be selected according to their medical conditions.

Adult↗